These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23088328)

  • 21. The Utilization of Low Dose Naltrexone for Chronic Pain.
    Poliwoda S; Noss B; Truong GTD; Creech ZA; Koushik SS; Urits I; Viswanath O
    CNS Drugs; 2023 Aug; 37(8):663-670. PubMed ID: 37505425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.
    Marciuch A; Brenna IH; Weimand B; Solli KK; Tanum L; Røstad BK; Birkeland B
    Addict Sci Clin Pract; 2022 Jul; 17(1):36. PubMed ID: 35850782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naltrexone Implant for Opioid Use Disorder.
    Edinoff AN; Nix CA; Orellana CV; StPierre SM; Crane EA; Bulloch BT; Cornett EM; Kozinn RL; Kaye AM; Murnane KS; Kaye AD
    Neurol Int; 2021 Dec; 14(1):49-61. PubMed ID: 35076607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study).
    Weimand BM; Solli KK; Reichelt WH; Tanum L
    Contemp Clin Trials Commun; 2021 Mar; 21():100728. PubMed ID: 33665469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual.
    Blum K; Lott L; Baron D; Smith DE; Badgaiyan RD; Gold MS
    J Syst Integr Neurosci; 2020 May; 7():. PubMed ID: 32934823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Sedation and Analgesia in Critically Ill Patients Receiving Long-Acting Naltrexone Therapy for Opioid Use Disorder.
    Petri CR; Richards JB
    Ann Am Thorac Soc; 2020 Nov; 17(11):1352-1357. PubMed ID: 32866026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation.
    Hyatt JM; Lobmaier PP
    Health Justice; 2020 Mar; 8(1):7. PubMed ID: 32172481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
    Krupitsky E; Blokhina E; Zvartau E; Verbitskaya E; Lioznov D; Yaroslavtseva T; Palatkin V; Vetrova M; Bushara N; Burakov A; Masalov D; Mamontova O; Langleben D; Poole S; Gross R; Woody G
    Lancet HIV; 2019 Apr; 6(4):e221-e229. PubMed ID: 30880163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.
    Molero Y; Zetterqvist J; Binswanger IA; Hellner C; Larsson H; Fazel S
    Am J Psychiatry; 2018 Oct; 175(10):970-978. PubMed ID: 30068260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the delivery of buprenorphine for opioid dependence.
    Rosenthal RN; Goradia VV
    Drug Des Devel Ther; 2017; 11():2493-2505. PubMed ID: 28894357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption.
    Benéitez MC; Gil-Alegre ME
    Biomed Res Int; 2017; 2017():7120815. PubMed ID: 28607934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioid Use in the Twenty First Century: Similarities and Differences Across National Borders.
    Vasilev G; Milcheva S; Vassileva J
    Curr Treat Options Psychiatry; 2016 Sep; 3(3):293-305. PubMed ID: 27493878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist.
    Thakarar K; Weinstein ZM; Walley AY
    Postgrad Med J; 2016 Jun; 92(1088):356-63. PubMed ID: 27004476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Themed section.
    Christie MJ; Connor M; Traynor JR
    Br J Pharmacol; 2015 Jan; 172(2):247-50. PubMed ID: 25537825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive approach to addiction medicine as an appropriate response to the HIV epidemic among drug users.
    Gerra G
    J Food Drug Anal; 2013 Dec; 21(4):S109-S112. PubMed ID: 25264413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs for addiction: a therapeutic area in need of a 'shot in the arm'.
    Malizia AL; Ferro A
    Br J Clin Pharmacol; 2014 Feb; 77(2):225-7. PubMed ID: 24450545
    [No Abstract]   [Full Text] [Related]  

  • 38. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.
    Kunøe N; Lobmaier P; Ngo H; Hulse G
    Br J Clin Pharmacol; 2014 Feb; 77(2):264-71. PubMed ID: 23088328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
    Lobmaier PP; Kunøe N; Gossop M; Waal H
    CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting depot formulations of naltrexone for heroin dependence: a review.
    Krupitsky EM; Blokhina EA
    Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.